A few steps stand between BioMarin Pharmaceutical Inc. and another rare disease drug approval. The San Rafael-based drug developer (NASDAQ: BMRN) believes improvements in a six-minute walking test by young patients with a crippling and deforming genetic disease, known as MPS IVA, is enough to secure Food and Drug Administration approval of its drug...